Loading...
•
Mar 31, 2022
Bicycle Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022 and provided recent corporate updates.
Key Takeaways
Bicycle Therapeutics reported interim data for the Phase I portion of the Phase I/II trial in BT8009, showing an overall response rate, or ORR, of 50% in the 5mg/m2 weekly cohort in patients with urothelial cancer and an encouraging tolerability profile. The company's cash and cash equivalents of $407.4 million as of March 31, 2022 are expected to provide financial runway through 2024.
Reported interim data for the Phase I portion of the Phase I/II trial in BT8009, showing an overall response rate, or ORR, of 50% in the 5mg/m2 weekly cohort in patients with urothelial cancer and an encouraging tolerability profile.
BT8009 has the potential to offer clinically meaningful differentiation compared to currently available therapies.
Initiating the BT5528 Phase II expansion cohorts soon.
Cash and cash equivalents will provide financial runway through 2024.
Forward Guidance
Bicycle's anticipated advancement of its product candidates, including BT8009, BT5528 and BT7480; the anticipated design of, initiation of expansion cohorts in, dosing in and progression of Bicycle’s clinical trials; the availability of data from clinical trials; the therapeutic potential for Bicycles in oncology and other applications; and Bicycle’s expected cash runway.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...